Background Low compliance to randomized nondrug interventions can affect treatment estimates of clinical trials. Cluster-randomized crossover may be appropriate for increasing compliance in the out-of-hospital cardiac arrest setting. Purpose The purpose was to determine whether the elapsed time from start of a nonblinded treatment period to episode enrollment date in a cluster-randomized crossover trial is associated with compliance to either a period of brief cardiopulmonary resuscitation (CPR) with electrocardiogram (ECG) rhythm analysis or a period of longer CPR with a delayed ECG rhythm analysis in patients with out-of-hospital cardiac arrest. Methods The Resuscitation Outcomes Consortium PRIMED Analyze Late (AL) versus Analyze Early (AE) trial was a cluster-randomized crossover trial at 10 North American regional sites. Clusters were created based on local service preference with treatment periods varying from 3 to 12 months depending on the expected enrollment rate of each randomizing unit. Episodes on the AL arm had a target of 180 s from CPR start to shock assessment and were deemed compliant if total time was between 150 and 210 s. Episodes on the AE arm had a target of <30 s from CPR start to shock assessment and were deemed compliant if total time was <60 s. We used logistic regression to examine the association between compliance (yes/no) and the elapsed number of days from the start of the treatment period to the episode in the framework of generalized estimating equations, controlling for randomized treatment (Late, reference = Early) and treatment period length (reference = 3, 4 -5, 6, 7 -11, and 12 months). Results We had 8769 episodes in our analysis population. Overall compliance to the randomized arm was 63.5%. After adjusting for treatment arm and treatment period length, the odds of compliance for episodes occurring >300 days from treatment period start were 33% lower (odds ratio (OR): 0.67; 95% confidence interval RH Schmicker Compliance in cluster crossover trials 2012 ARTICLE Compliance in cluster crossover trials 315 http://ctj.sagepub.com Clinical Trials 2012; 9: 314 -321 (CI): 0.52, 0.86) than for those <60 days from treatment period start. There was no significant difference in compliance between episodes before and immediately after a cluster crossed over to the opposite arm (OR: 0.81; 95% CI: 0.57, 1.16). Limitations A major challenge was the lack of synchronicity between training cycles and agency crossover dates. Conclusion We found a significant decrease in compliance to the AL versus AE cardiac arrest intervention as the elapsed time from start of treatment period increased. We did not find a difference in compliance immediately before and after a crossover. While these results suggest that future cluster with crossover trials in the out-of-hospital setting be designed with short treatment periods and frequent crossovers, provider logistical concerns must also be considered. Clinical Trials 2012; 9: 314-321.
Introduction
Intent-to-treat (ITT) analyses, supported by the Food and Drug Administration (FDA) and National Institutes of Health (NIH), are the most appropriate methods for assessing the utility of an intervention under ordinary settings [1] . The results from ITT analyses are in terms of the assigned treatment and are often more conservative than those in the ideal setting. Interventions found to be advantageous in the ideal setting may not be advantageous in the ordinary setting if implementation is challenging. As such when developing a protocol for a process of care intervention thought to be advantageous in the ordinary setting, it is important to maximize the rates of compliance by ensuring that the intervention is of minimal complexity [1] .
One area that can be prone to high noncompliance is nondrug, emergency research in the prehospital setting. This dynamic setting is highly complex, is high pressured, and has been shown to cause great stress in those that provide medical care [2] . Initial skills and knowledge are acquired by emergency medical providers from certification program training and then reinforced during periodic retraining programs [3] . When implementing clinical trials, emergency medical providers are trained in new study-specific skills. If skill retention is most often maintained through frequent repetition, one can expect a high rate of noncompliance for skills infrequently used. Out-of-hospital cardiac arrest is a rare event [4] that individual emergency medical providers may not encounter over the span of a year. As such, most providers may not achieve a satisfactory level of comfort with a new and infrequently applied intervention.
Cluster randomization, where providers are assigned the same treatment over a defined period of time, may be appropriate for minimizing noncompliance in the out-of-hospital cardiac arrest setting compared to individual randomization, where the assigned treatment may be different with each incident. While logistically simpler, cluster randomization presents statistical challenges that result in an increase in sample size [5] .
A common method to counter the increase in sample size due to between cluster variance, is to include a crossover in the design [6] . For nonreoccurring events, individual patients in cluster randomization with crossover (CRC) trials do not cross over from one treatment to the next but rather the group of patients who are in a geographical region will be eligible for another treatment based on a predefined time period.
The Resuscitation Outcomes Consortium (ROC) is a clinical trial network that conducts emergency medical service (EMS)-based out-of-hospital research performed by licensed paramedic and fire personnel in patients with cardiac arrest or severe traumatic injuries. The ROC PRIMED Analyze Late (AL) versus Analyze Early (AE) trial examined a behavioral method of performing 3 min of cardiopulmonary resuscitation (CPR) prior to electrocardiogram (ECG) rhythm analysis (AL) compared with up to 60 s of CPR prior to ECG rhythm analysis (AE) in adults who experienced a cardiac arrest in the out-of-hospital setting. The study was performed under a CRC design where treatment period lengths varied across regions. We evaluated whether the CRC design contributed to noncompliance by emergency medical providers. Specifically, the purpose of this study was to determine whether compliance changed over time and whether there was an initial change in compliance during the time period immediately following a crossover.
Methods
The ROC PRIMED trial qualifies for exception from informed consent for emergency research as outlined in US FDA regulation 21CFR50.24 and the Canadian Tri-Council Agreement for research in emergency health situations (Article 2.8). The ROC PRIMED AL Versus AE trial, described in detail elsewhere [7] , compared survival to hospital discharge with modified Rankin Score ≤ 3 between a strategy of AL versus a strategy of AE. The AL versus AE trial Clinical Trials 2012; 9: 314 -321 http://ctj.sagepub.com used a CRC design because investigators did not feel that individual randomization was appropriate in the emergency setting. CPR is a behavioral method initiated by the medical providers upon arrival to the scene. Randomizing individual episodes through envelopes or phone calls would add unneeded onscene complexity and dynamics to the resuscitative effort, may delay lifesaving treatment, and enrollment may be subject to selection bias. In addition, the risk of a carryover effect would be high if medical providers were forced to change methods on an episode-by-episode basis. Cluster plans were created for each of 10 ROC sites based on logistical and statistical considerations. The most common plan was randomization at the agency level, defined as a Fire Department, EMS or Emergency Rescue Service. Cluster sizes (the total number of episodes in a cluster after receiving both interventions) were planned to contain a similar number of episodes (<100) in an attempt to minimize the design effect [5] . However, since the agency enrollment varies in size from 1/month to 70/month across the consortium, to keep cluster size within the desired range, high enrolling agencies were encouraged to have shorter treatment periods (3 or 4 months) or to increase the number of clusters by dividing into smaller units. The latter resulted in randomization at subdivisions: an automated external defibrillator (AED)/defibrillator, rig (an individual motor vehicle), station (a group of vehicles located in one physical location), or battalion (a group of stations). The Regional Coordinating Centers, in collaboration with the agency's medical directors and administration, determined the most appropriate method for the agency. Many decisions were based on the feasibility of crossing over to a new intervention more frequently or the appropriateness of two separate rigs arriving on scene randomized to different arms of the study. The few ROC agencies that opted to randomize by rig did so with treatment periods of 12 months. Clusters began enrolling patients at different times over the course of the study. Upon study initiation, clusters were randomized to either the AL or AE treatment. Clusters began enrollment in a Run-In Phase during which compliance was monitored and performance feedback was given. Clusters that were able to meet compliance benchmarks as determined by the ROC Study Monitoring Committee (SMC) were advanced to the Evaluable Phase. Clusters that were unable to meet the benchmarks within 2-6 months of Run-In Phase commencement were no longer eligible to participate in the trial. Once in the Evaluable Phase, clusters retained the same randomization arm as in the Run-In Phase for a prespecified length of time called the treatment period length. Once the assigned treatment period was completed, the cluster switched over to the opposite treatment arm. Upon completion of both treatment arms, clusters were rerandomized by the Data Coordinating Center (Figure 1 ). Clusters were alerted to the assigned treatment arm as close to the date of the cluster crossover as possible, usually within 1-2 months, to avoid provider bias. For purposes of this study, the term treatment arm will refer to either AL or AE, the term treatment period will refer to the unit of time on one treatment arm, and the term treatment period length will refer to the specific amount of time the treatment period was assigned to either treatment arm prior to crossover.
Statistical methods
Our analysis excluded all cases in the Run-In Phase since compliance increased over time as a result of targeted efforts to meet minimum benchmarks to move into the Evaluable Phase. Clusters that initially met the benchmarks spent less time in the Run-In Phase than those that had to improve over time. Thus, we were concerned that including the Run-In Phase data may bias our results. One agency had randomization performed at the AED/defibrillator level. Within this agency, each AED/defibrillator was randomized to one of the two treatment arms. The AED/ defibrillator software was then programmed to provide medical providers with real-time prompts to assess the rhythm after either 60 or 180 s of CPR, depending on the randomized treatment arm. We excluded all episodes from this agency as we felt that such active instructions during the course of care would be different and have higher compliance than those that relied on passive reminders and prior training. Our final analysis population also excluded from the evaluable population all episodes with missing CPR to shock assessment time, episodes that were EMS witnessed, and episodes with any study-specific exclusions. The descriptive statistics were created to examine unadjusted results and trends in the analysis population over the course of the Evaluable Phase.
To examine the association between compliance and time from start of treatment period, we used logistic regression in the framework of generalized estimating equations (GEEs) with compliance modeled as a binary variable. The SMC deemed episodes on the AE arm compliant if the time from initiation of CPR to shock assessment is less than 60 s, whereas episodes on the AL arm were deemed compliant if the time was between 150 and 210 s. We calculated elapsed time as the difference between the start date of the respective treatment period and the episode date and created a categorical variable by cutting elapsed time by 60-day increments. We adjusted for two potential confounders: randomized treatment arm (AL, reference = AE) and treatment period length (reference = 3, 4-5, 6, 7-11, and 12 months). We used randomized cluster as the clustering variable in GEE, with an exchangeable working covariance structure and robust standard errors.
To examine whether there is an association between crossing over to the opposite arm and compliance, we examined episodes in the first treatment period and those in the first 2 weeks of the second treatment period. Episodes in clusters that did not cross over were excluded from the analysis. We used logistic regression with similar structure as above and included a variable that represented whether the episode occurred prior to or in the 2-week period immediately following the crossover.
To examine whether there is a long-term trend, we examined if compliance in the first treatment period was different than compliance in the third treatment period, for those clusters that had a third treatment period. Clusters with third treatment periods were rerandomized once and had a 50% chance of having the same randomization arm during the third period as during the first. We used logistic regression with similar structure as above and included a variable that represented the treatment period.
Data manipulation was done in S-PLUS (version #6. 
Results
After excluding episodes as defined in the 'Methods' section (Run-In Phase = 25%, defibrillator randomization = 7%), we had 11,388 episodes in the Evaluable Phase. We then excluded any episodes with study-specific exclusions (EMS witnessed = 11%, written do not resuscitate orders = 3%, nonfire/EMS rhythm = 3%, age = 2%, and others = 2%) as well as those with missing time from CPR start to shock assessment (3%). The final analysis population ( Figure 2 ) consisted of 8767 patients across 350 clusters and 10 sites. Episodes occurred in one of six treatment periods, where treatment period 1-1 represented the initial post-Run-In Phase period, while treatment period 1-2 represented the period after having crossed over for the first time. Treatment period 2-1 then represents the period after rerandomization and following the completion of the first two treatment periods. Table 1 shows the frequencies of each assigned treatment period length. The majority of clusters (88.6%) were either 6 or 12 months long. Figure 3 shows unadjusted compliance to the randomized treatment arm by the treatment period length. The highest compliance rates occurred in clusters with 6-month treatment periods (AE = 73.7%, AL = 67.5%) but varied across all treatment periods. The overall compliance rate was 63.5% (AE = 65.3%, AL = 61.5%). Figure 4 shows unadjusted Clinical Trials 2012; 9: 314 -321 http://ctj.sagepub.com compliance to the randomized treatment arm by the elapsed time between the start of treatment period and episode date. The highest rates of AE compliance occurred in the 61-to 120-day period (68.3%), while the highest rates of AL compliance occurred in the 0-to 60-day period (63.4%). After adjusting for treatment arm (AL, reference = AE) and treatment period length (reference = 3, 4-5, 6, 7-11, and 12 months), elapsed time from the start of the treatment period to episode date is significantly associated (χ 2 (5) = 11.8, p = 0.04) with compliance when cluster was used as the clustering variable. This significance is driven by the odds of compliance for episodes >300 days from treatment period start date in comparison to episodes <60 days from treatment period start (odds ratio (OR): 0.67; 95% confidence interval (CI): 0.52, 0.86) ( Table 2 ). In the same model, randomized treatment period length (χ 2 (4) = 23.6, p < 0.01) was found to be significantly associated with compliance. In a sensitivity analysis, elapsed time from the start of the treatment period to episode date is significantly associated (χ 2 (5) = 13.5, p = 0.02) with the absolute deviation from the intervention target when adjusted for the same covariates as above. The significance is driven by the increase in absolute deviation for episodes > 300 days from treatment start date in comparison to episodes <60 days from treatment period start (β: 11.3sec.; 95% CI: 0.5, 22.2) ( Table 3) .
Three hundred and nine clusters crossed over at least once to the opposite arm. Within this subgroup of clusters, 236 episodes fell within a 2-week period after the first assigned crossover date. After adjusting for treatment arm, treatment period length and elapsed time, the odds of compliance were not significantly lower (OR: 0.81; 95% CI: 0.57, 1.16) in the first 2 weeks after crossover in comparison to before the crossover (Table 4 ).
In a subgroup of episodes from clusters that were rerandomized after having completed two full treatment periods (n = 31 clusters, 1445 episodes), there was no significant association when comparing compliance in the third treatment period to that of the first treatment period (OR: 1.00; 95% CI: 0.98, 1.01) when adjusted for elapsed time, treatment period length, and treatment arm. 
Discussion
In a cluster-randomized crossover trial comparing two strategies of CPR in the out-of-hospital emergency setting, we found a significant association between elapsed time from start of the treatment period to the episode date and compliance to the assigned treatment arm. Specifically, episodes occurring >300 days after their respective treatment period start had 33% lower odds of compliance compared to episodes < 60 days after the treatment period start. One possible explanation for this result is the minimal number of cardiac arrest cases seen per year by individual out-of-hospital emergency providers. Across the ROC network, we estimate that 36,000 medical providers [8] treat 20,500 patients with cardiac arrests each year [4] . This suggests that the average medical provider may likely treat one cardiac arrest per year. Medical providers gain familiarity with standard American Heart Association (AHA) resuscitation guidelines through repetition. The same familiarity may not be achievable with new research protocols if they are not reinforced through training or performed often enough. In our study, this appears to be especially true if the cardiac arrest occurs 300 days or more from the start of the treatment period.
By adjusting for the treatment period length in our model, we accounted for the fact that not all clusters would be able to treat an event 300 days from the initial start date. Our results show that treatment period length is significantly associated with compliance, with episodes in clusters with 6and 12-month treatment periods having 40% and 21% greater odds of compliance than those in clusters with 3-month treatment periods, regardless of the actual number of elapsed days from the start of the treatment period. This suggests that the agencies that opted for 6-and 12-month treatment periods had a higher baseline compliance rate than those with a 3-month treatment period.
In a subgroup of episodes occurring in clusters that completed at least two full treatment periods, we did not find a significant difference in compliance between episodes in the first treatment period and the third treatment period. This result suggests that compliance does decrease over time but only inside of treatment periods and not across treatment periods.
This appears to be consistent with our finding that compliance in the 2-week period immediately following the initial crossover is not significantly lower than in the entire previous treatment period. We hypothesized that compliance after the crossover would be worse because of a carryover effect, which may be relevant in high-density regions where medical providers see multiple cardiac arrests but irrelevant in low-density regions where cardiac arrest is rare. However, the carryover effect did not appear to be an issue in our study. This unexpected finding could be the result of increased communication between agencies and their medical providers. ROC clinical sites employed multiple strategies simultaneously to inform medical providers of the appropriate randomization arm upon crossover. These strategies include in-house slide shows or web-based modules and reminders posted to the dashboard of rigs, defibrillator cases, or in common work areas. Each appears to have helped maintain compliance at similar rates across treatment periods.
In the primary analysis for the trial, Stiell et al. did not find a significant association between randomized treatment arm and survival to hospital discharge with a modified Rankin Score ≤ 3. The trial was designed in a way to encourage high compliance rates within clusters, knowing that high rates of noncompliance in an ITT analysis can push the effectiveness estimates toward zero. There was concern that the overall compliance rate of 63.5% may have been a factor in the null result. However, in a secondary analysis based on the actual treatment received, the treatment estimates were also not significant, suggesting that the high rates of noncompliance were not solely responsible for the nonsignificant effectiveness estimates in this trial [9] .
Even though it is fortunate that a degree of noncompliance did not affect the significance of our effectiveness estimate, it is preferred to design future studies to increase compliance. Any change in the study design, however, must be measured against emergency provider logistical concerns. Expressed concerns about the design were the difficulty in scheduling retraining programs and the feasibility of posting reminders in stations and vehicles upon crossover to the new intervention. The latter was labor intensive and often outside job descriptions for many medical providers. As partners in research, investigators need to consider feedback from the medical providers and design a study that is statistically sound, practical to implement, and meaningful.
A major challenge in conducting the trial was the lack of synchronicity between training cycles and crossover dates. All participating agencies trained their medical providers to the two treatment arms prior to commencement in this study (in some instances more than once due to delayed regulatory approval). However, due to set training cycles, time, and personnel limitations, very few provided physical retraining immediately prior to crossover dates. While most agencies had reminder materials posted throughout the stations and rigs, many providers would have to implement a new intervention that they were physically trained on months prior.
In future trials of emergency medicine research with crossover, it may be wise to schedule the study start and crossovers to be in sync with the retraining at the agencies. This will require flexibility between not just study investigators and medical providers but with regulatory bodies as well. This represents a
